= Emerging. More than 5 years before clinical availability. (9.82%)
= Expected to be clinically available in 1 to 4 years. (12.95%)
= Clinically available now. (22.77%)
MSACL 2018 EU : Toth

MSACL 2018 EU Abstract

Topic: Proteomics

Podium Presentation in the Ether on Thursday at 15:10 (Chair: Yuri van der Burgt)

In Depth Proteomic Analysis of Prostate Cancer Biopsies

Gabor Toth (Presenter)
Hungarian Academy of Sciences

Presenter Bio(s): My name is Gábor Tóth, I graduated as a chemical engineer at the Budapest University of Technology and Economics. I am at the beginning of my professional scientific career as I proceeded with starting my Ph.D. programme from July 2018 on.
I have now been a student researcher at the MS Proteomics Group of the Research Centre for Natural Sciences, Hungarian Academy of Sciences for four years and despite being a chemical engineer I am dedicated to life science research. My Ph.D. program is related to clinical proteomics, the main aim is to discover possible new biomarkers for prostate cancer.
I am completely overwhelmed with the depth of natural sciences, I have always loved solving problems and searching for the reasons behind the events, therefore it is a great pleasure to step on this path.

Authors: Gábor Tóth (1,2), Oliver Ozohanics (1), András Ács (1,3), Ágnes Révész (1), Károly Vékey (1), László Drahos (1), Lilla Turiák (1)
(1) MS Proteomics Research Group, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Magyar tudósok körútja 2., H-1117 Budapest, Hungary (2) Budapest University of Technology and Economics, Faculty of Chemical Technology and Biotechnology, Műegyetem rkp. 3., H-1111 Budapest, Hungary (3) Semmelweis University, PhD School of Pharmaceutical Sciences, Üllői út 26., H-1085 Budapest, Hungary

Abstract

Cancer research is among the most studied areas of science and prostate cancer (PCa) is one of the most common types of cancer among men. In this work we describe a detailed proteomics analysis of PCa tissue microarrays (TMAs) with our novel methodology. It is based on surface proteolytic digestion and proved to be capable of quantifying over 500 proteins from a single 1.5 mm diameter TMA core. We have compared the protein composition of tissues with various grades and stages of cancer. Samples from healthy and cancerous tissues were clearly distinguished and a good correlation with cancer grade was found. A well balanced study was carried out and over 100 proteins showed statistically significant abundance changes between various groups. During STRING evaluation up-regulation eg. in KEGG ribosome pathway and mRNA splicing could be observed.


Financial Disclosure

DescriptionY/NSource
Grantsno
Salaryno
Board Memberno
Stockno
Expensesno
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above:

no